The location of this non-synonymous polymorphism in the thyroglobulin (TY) domain of the EPCAM gene suggests its role in inhibiting cathepsins, a family of cysteine proteases that are frequently secreted by tumour cells during metastasis [43]. This evidence concerns the gene EPCAM and neoplasm.